Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50

Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50 Years Using 40 Type 2 Diabetes Risk Single Nucleotide Polymorphisms Diabetes Care January 2011 34:121-125; published ahead of print October 1, 2010,  LINK

 

R lattice graphics plots

multivariate data visualization R

lattice
http://lmdvr.r-forge.r-project.org/figures/figures.html

examples with code

novel reversible anticoagualtion - RNA aptamers - anti FIX

RADAR: First significant clinical use of novel reversible anticoagulation system

April 6, 2011 | Sue Hughes

New Orleans, LA - A phase 2 trial of a novel anticoagulation system that involves first giving a factor IX inhibitor and then administering a reversal agent has shown preliminary encouraging results, albeit with a question about potential allergic reactions.

REG1 (Regado Biosciences) consists of an RNA aptamer of factor IX—pegnivacogin—which binds to and inhibits the factor IX molecule for a 24-hour duration, and the reversal agent—anivamersen, which binds to and inactivates pegnivacogin.

from heart.org

http://www.springerlink.com/content/e2624407h271h2k2/fulltext.pdf